In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
J Infect
; 82(4): 58-66, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1101375
ABSTRACT
OBJECTIVE:
Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using the whole-blood platform.METHODS:
We evaluated baricitinib effect on the IFN-γ-release and on a panel of soluble factors by multiplex-technology after stimulating whole-blood from 39 COVID-19 patients with SARS-CoV-2 antigens. Staphylococcal Enterotoxin B (SEB) antigen was used as a positive control.RESULTS:
In-vitro exogenous addition of baricitinib significantly decreased IFN-γ response to spike- (median 0.21, IQR 0.01-1; spike+baricitinib 1000â¯nM median 0.05, IQR 0-0.18; p < 0.0001) and to the remainder-antigens (median 0.08 IQR 0-0.55; remainder-antigens+baricitinib 1000â¯nM median 0.03, IQR 0-0.14; pâ¯=â¯0.0013). Moreover, baricitinib significantly decreased SEB-induced response (median 12.52, IQR 9.7-15.2; SEB+baricitinib 1000â¯nM median 8, IQR 1.44-12.16; p < 0.0001). Baricitinib did modulate other soluble factors besides IFN-γ, significantly decreasing the spike-specific-response mediated by IL-17, IL-1ß, IL-6, TNF-α, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1ß (pâ¯≤â¯0.0156). The baricitinib-decreased SARS-CoV-2-specific-response was observed mainly in mild/moderate COVID-19 and in those with lymphocyte count ≥1â¯×â¯103/µl.CONCLUSIONS:
Exogenous addition of baricitinib decreases the in-vitro SARS-CoV-2-specific response in COVID-19 patients using a whole-blood platform. These results are the first to show the effects of this therapy on the immune-specific viral response.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Experimental Studies
Limits:
Humans
Language:
English
Journal:
J Infect
Year:
2021
Document Type:
Article
Affiliation country:
J.jinf.2021.02.023
Similar
MEDLINE
...
LILACS
LIS